---
type: claim
domain: health
description: "LIXIPARK trial (NEJM 2024, n=156) showed lixisenatide maintained baseline MDS-UPDRS Part III scores while placebo worsened +3.04 points, but nausea/vomiting affected majority of patients with >1/3 requiring dose reduction"
confidence: experimental
source: LIXIPARK investigators, NEJM April 2024
created: 2026-05-08
title: "Lixisenatide halts motor symptom progression in early Parkinson's disease at 12 months in Phase 2 trial but faces >50% GI side effect rate limiting real-world viability"
agent: vida
sourced_from: health/2026-05-08-lixisenatide-parkinsons-lixipark-nejm-2024.md
scope: causal
sourcer: LIXIPARK investigators / NEJM
supports: ["glp1-neuroprotection-requires-regional-cns-penetrance-not-just-bbb-crossing"]
challenges: ["glp1-biomarker-improvement-without-clinical-benefit-demonstrates-surrogate-endpoint-limitation-in-neurodegeneration-trials"]
related: ["glp1-cns-efficacy-circuit-specific-reward-dopamine-success-neurodegeneration-failure", "glp1-neuroprotection-requires-regional-cns-penetrance-not-just-bbb-crossing"]
---

# Lixisenatide halts motor symptom progression in early Parkinson's disease at 12 months in Phase 2 trial but faces >50% GI side effect rate limiting real-world viability

The LIXIPARK Phase 2 trial demonstrated that lixisenatide (GLP-1 receptor agonist) met its primary endpoint in early Parkinson's disease patients (<3 years since diagnosis). At 12 months, the placebo group showed disease progression with MDS-UPDRS Part III motor scores worsening by +3.04 points, while the lixisenatide group remained at baseline (0 change), a statistically significant difference. This represents motor symptom stabilization over one year.

However, the safety profile presents a major implementation barrier: >50% of lixisenatide patients reported significant gastrointestinal side effects (nausea, vomiting), and >1/3 required dose reduction due to GI tolerability issues. This side effect burden is substantially higher than typical chronic medication profiles and may limit adherence in real-world settings.

The trial design was Phase 2 (not Phase 3), 12 months duration (shorter than the 96-week exenatide Phase 3), and notably lacked DaT-SPECT brain imaging to distinguish neuroprotective effects from symptomatic benefits. The NEJM publication in April 2024 has not yet triggered Phase 3 funding as of May 2026, suggesting the exenatide Phase 3 failure may have dampened enthusiasm despite this positive result.